Cat. No.: HY-N4201

β-Hydroxyisovalerylshikonin

Avis client

Based on 1 Customer Validation

Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermum erythrorhizon, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC₅₀s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.83%
CAS No.: 7415-78-3
Formule: C₂₁H₂₄O₇
Masse moléculaire:388.41

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

β-Hydroxyisovalerylshikonin Chemical Structure

CAS No.: 7415-78-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

IC50: 0.7 μM (EGFR), 1 μM (v-Src)^[1]

Voir tous les produits spécifiques à Isoform EGFR :

Voir tous les produits spécifiques à Isoform Src :

Cellular Effect

Cell Line	Type	Value	Description	References
BTI-TN-5B1-4	IC₅₀	169.8 μM Compound: 3	Inhibition of human ACAT2 expressed in Hi5 cells Inhibition of human ACAT2 expressed in Hi5 cells	[PMID: 17157006]
BTI-TN-5B1-4	IC₅₀	186.9 μM Compound: 3	Inhibition of human ACAT1 expressed in Hi5 cells Inhibition of human ACAT1 expressed in Hi5 cells	[PMID: 17157006]
CCRF-CEM	IC₅₀	0.6 μM Compound: 1	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 22530779]
DU-145	IC₅₀	16.8 μM Compound: 2, beta-HIVS	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 21689869]
HCT-116	IC₅₀	0.37 μM Compound: 14	Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay	[PMID: 17949858]
HCT-116	IC₅₀	4.1 μM Compound: 1	Cytotoxicity against human HCT116 cells after 72 hrs by XTT assay Cytotoxicity against human HCT116 cells after 72 hrs by XTT assay	[PMID: 22530779]
HeLa	IC₅₀	55 μM Compound: 2, beta-HIVS	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 21689869]
HepG2	IC₅₀	0.59 μM Compound: 14	Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay	[PMID: 17949858]
MDA-MB-231	IC₅₀	4.6 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by XTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by XTT assay	[PMID: 22530779]
MRC5	IC₅₀	3.9 μM Compound: 1	Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay	[PMID: 22530779]
SBcl2	IC₅₀	8.3 μM Compound: 1	Cytotoxicity against human SBcl2 cells after 72 hrs by XTT assay Cytotoxicity against human SBcl2 cells after 72 hrs by XTT assay	[PMID: 22530779]
U-251	IC₅₀	23.6 μM Compound: 1	Cytotoxicity against human U251 cells after 72 hrs by XTT assay Cytotoxicity against human U251 cells after 72 hrs by XTT assay	[PMID: 22530779]
WM164	IC₅₀	30.9 μM Compound: 1	Cytotoxicity against human WM164 cells after 72 hrs by XTT assay Cytotoxicity against human WM164 cells after 72 hrs by XTT assay	[PMID: 22530779]

Chemical Information

CAS No. 7415-78-3
Appearance Solid
Masse moléculaire 388.41
Formule C₂₁H₂₄O₇
Color Brown to black
SMILES

CC(C)(O)CC(O[C@@H](C(C1=O)=CC(C2=C1C(O)=CC=C2O)=O)C/C=C(C)\C)=O
Structure Classification
- Quinones
- Naphthalene Quinones
- Phenols
- Polyphenols
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvant et solubilité

In Vitro:

DMSO : 10 mg/mL (25.75 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5746 mL

12.8730 mL

25.7460 mL

5 mM

0.5149 mL

2.5746 mL

5.1492 mL

10 mM

0.2575 mL

1.2873 mL

2.5746 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (2.57 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (2.57 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (277 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Hashimoto S, et al. Beta-hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases. Jpn J Cancer Res. 2002 Aug;93(8):944-51. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5746 mL	12.8730 mL	25.7460 mL	64.3650 mL
	5 mM	0.5149 mL	2.5746 mL	5.1492 mL	12.8730 mL
	10 mM	0.2575 mL	1.2873 mL	2.5746 mL	6.4365 mL
	15 mM	0.1716 mL	0.8582 mL	1.7164 mL	4.2910 mL
	20 mM	0.1287 mL	0.6436 mL	1.2873 mL	3.2182 mL
	25 mM	0.1030 mL	0.5149 mL	1.0298 mL	2.5746 mL

Keywords

β-Hydroxyisovalerylshikonin

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

β-Hydroxyisovalerylshikonin

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

Anti-Cancer Compound Library

Covalent Screening Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Quinones Library

Mass Spectrometry Natural Product Library

Voir tous les produits spécifiques à Isoform EGFR

Voir tous les produits spécifiques à Isoform Src

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

β-Hydroxyisovalerylshikonin Related Classifications

HY-N4201 Related Classifications